PQR620

Cat. No.: HY-100026
CAS No.: 1927857-56-4
Molecular Formula: C₂₁H₂₅F₂N₇O₂
Molecular Weight: 445.47
Target: mTOR
Pathway: PI3K/Akt/mTOR
Storage:
- Powder: -20°C 3 years, 4°C 2 years, In solvent: -80°C 6 months, -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO : 6.4 mg/mL (14.37 mM; Need warming)

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>Mass 1 mg</th>
<th>Mass 5 mg</th>
<th>Mass 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.2448 mL</td>
<td>11.2241 mL</td>
<td>22.4482 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4490 mL</td>
<td>2.2448 mL</td>
<td>4.4896 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2245 mL</td>
<td>1.1224 mL</td>
<td>2.2448 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
PQR620 is a novel potent and selective brain penetrant inhibitor of mTORC1/2.

IC₅₀ & Target

<table>
<thead>
<tr>
<th>mTORC1</th>
<th>mTORC2</th>
</tr>
</thead>
</table>

In Vitro
PQR620 is a potent and selective mTOR inhibitor, which induces >1000-fold selectivity towards mTOR over PI3Kα in enzymatic binding assays. In A2058 melanoma cells PQR620 demonstrates inhibition of protein kinase B (pSer473)
and ribosomal protein S6 (pSer235/236) phosphorylation with IC\textsubscript{50} values of 0.2 μM and 0.1 μM, respectively. PQR620 shows excellent selectivity over a wide panel of kinases, as well as excellent selectivity versus unrelated receptor enzymes and ion channels. PQR620 demonstrates its potency to prevent cancer cell growth in an NTRC 44 cancer cell line panel, resulting in a 10\log(\text{IC}_{50}) of 2.86 (nM)\textsuperscript{[1]}. PQR620 has a median IC\textsubscript{50} of 250 nM when tested on 44 lymphoma cell lines. Activity is higher in B cell than in T cell tumors (median IC\textsubscript{50}: 250 nM vs 450 nM; P=0.002). At 72h, anti-tumor activity of PQR620 is mostly cytostatic and apoptosis induction is seen only in 6/44 cell lines (13%). Sensitivity to PQR620 or apoptosis induction does not differ between DLBCL and MCL, and they are not affected by the DLBCL cell of origin, by TP53 status or by the presence of MYC or BCL2 translocations\textsuperscript{[2]}.

### In Vivo

The physico-chemical properties of PQR620 result in good oral bioavailability and excellent brain penetration\textsuperscript{[1]}. The activity of PQR620 as single agent undergoes in vivo evaluation in two DLBCL models, the germinal center B cell type DLBCL (GCB-DLBCL) SU-DHL-6 and the activated B cell-like DLBCL (ABC-DLBCL) RIVA. Treatments with PQR620 (100 mg/kg dose per day, Qd×7/w) start with 100-150 mm\textsuperscript{3} tumors and are carried for 14 (SU-DHL-6) or 21 days (RIVA). In both models, PQR620 determines a 2-fold decrease of the tumor volumes in comparison with control, with significant differences in both SU-DHL-6 (D7, D9, D11, D14; P<0.005) and RIVA (D14, D16, D19, D21; P<0.005)\textsuperscript{[2]}.

### PROTOCOL

#### Cell Assay \textsuperscript{[2]}

The drug concentration causing 50% inhibition of cell proliferation (IC\textsubscript{50}) is obtained in lymphoma cell lines [diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma (MCL); anaplastic large T-cell lymphoma; and others] exposed to increasing doses of PQR620 for 72 h using a Tecan D300e Digital Dispenser on 384 well plates\textsuperscript{[2]}. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration \textsuperscript{[2]}

**Mice**\textsuperscript{[2]}

For in vivo experiments, NOD-Scid (NOD.CB17-Prkdcscid/J) mice are subcutaneously inoculated with 10\times10\textsuperscript{6} (RIVA) or with 5\times10\textsuperscript{6} (SU-DHL-6) cells. Treatments with PQR620 (100mg/kg dose per day, Qd×7/w) started with 100-150 mm\textsuperscript{3} tumors and are carried for 14 (SU-DHL-6) or 21 days (RIVA). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES
